Literature review on the immunogenicity of herpes zoster vaccines .: HP40-243/2018E-PDF
"Herpes zoster is an acute viral infection caused by reactivation of varicella-zoster virus (VZV). LZV, a live, attenuated vaccine for zoster has been available in Canada for many years. A new subunit recombinant zoster vaccine (RZV) named Shingrix was approved in Canada in October 2017. This zoster vaccine immunogenicity review was done to have a comprehensive understanding of the immunogenicity of both live and subunit vaccines"--Executive summary, p. 3.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.865656&sl=0
| Department/Agency | Public Health Agency of Canada. |
|---|---|
| Title | Literature review on the immunogenicity of herpes zoster vaccines . |
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Format | Electronic |
| Electronic document | |
| Note(s) | Issued also in French under title: Revue de la littérature sur l'immunogénicité des vaccins contre le zona. "Publication date: January 2019." "An Advisory Committee Review (ACR), National Advisory Committee on Immunization (NACI)." Cover title. Includes bibliographical references. |
| Publishing information | [Ottawa] : Public Health Agency of Canada, 2019. |
| Description | 46 p. |
| ISBN | 9780660288628 |
| Catalogue number |
|
| Departmental catalogue number | Pub. : 180582 |
| Subject terms | Immunization |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.- Date modified: